From NEJM Journal Watch, this podcast features lively interviews, concise summaries, and expert commentary that busy clinicians need to stay current and improve patient care.
All content for Clinical Conversations is the property of NEJM Group and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
From NEJM Journal Watch, this podcast features lively interviews, concise summaries, and expert commentary that busy clinicians need to stay current and improve patient care.
Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate
Clinical Conversations
11 minutes 24 seconds
3 years ago
Podcast 293: HER2-“low” breast cancer and its reponse to an antibody-drug conjugate
Patients with metastatic breast cancer whose tumors express low levels of HER2 are generally classified and treated as having HER2-negative disease. However, Dr. Shanu Modi of the Memorial Sloan Kettering Cancer Center and a group of international collaborators explored the use of a monoclonal antibody–drug conjugate (trastuzumab–deruxtecan) in patients with disease they classify as HER2-“low.” Compared […]
Clinical Conversations
From NEJM Journal Watch, this podcast features lively interviews, concise summaries, and expert commentary that busy clinicians need to stay current and improve patient care.
